Hepatitis B
AASLD 2011: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 08 November 2011 00:00
- Written by Jennerex
A genetically engineered vaccinia poxvirus (JX-594) can rapidly destroy tumors and prolong survival of people with advanced hepatocellular carcinoma (HCC), according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
AASLD 2011: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Gilead Sciences
Most chronic hepatitis B patients who maintain viral suppression on tenofovir (Viread) for 5 years experience improvement in liver histology, including regression of cirrhosis, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
ICAAC 2011: Double Dose of Hepislav Works as Well as 3 Doses of Standard HBV Vaccine
- Details
- Category: HBV Prevention
- Published on Friday, 07 October 2011 00:00
- Written by Dynavax
Two injections of Dynavax's investigational Heplisav hepatitis B virus (HBV) vaccine protected adults over age 40 as well as the standard regimen consisting of 3 doses of the Engerix-B vaccine given over 6 months, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
Some People with Hepatitis B May Need Liver Cancer Screening Sooner and More Often
- Details
- Category: Hepatitis B
- Published on Friday, 04 November 2011 00:00
- Written by Liz Highleyman
Asian immigrants in the U.S. who have chronic hepatitis B virus (HBV) infection may develop hepatocellular carcinoma (HCC) at younger-than-expected ages, suggesting that people with risk factors such as smoking and family history should start liver cancer screening sooner and receive it more frequently, according to a report in the September 13, 2011, advance edition of the American Journal of Gastroenterology.
Entecavir (Baraclude) Less Effective for Patients with Multidrug-Resistant Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 October 2011 00:00
- Written by Liz Highleyman
The nucleoside analog antiviral drug entecavir (Baraclude) was minimally effective against hepatitis B virus (HBV) that had already developed resistance to lamivudine (Epivir-HBV) and adefovir (Hepsera), researchers reported in the October 2011 Journal of Viral Hepatitis. Patient who achieved good early response, however, can do well if they stay on entecavir.
CDC Advisory Committee Recommends Hepatitis B Vaccine for People with Diabetes
- Details
- Category: HBV Vaccines
- Published on Tuesday, 01 November 2011 00:00
- Written by Liz Highleyman
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) last week recommended that adults up to age 60 with diabetes should be vaccinated against hepatitis B virus (HBV), as this group has a higher risk of infection compared with the general population.
Changes Proposed for Allocation of Donated Livers
- Details
- Category: Liver Transplant - HBV
- Published on Thursday, 01 September 2011 00:00
- Written by Wiley-Blackwell
For some patients transplantation is the only treatment for advanced liver disease due to chronic hepatitis B, hepatitis C, liver cancer, alcoholism, or other causes. But the supply of donor livers does not meet the demand, meaning that many people die while on a waiting list. As described in the September 2011 issue of Liver Transplantation, experts have been meeting for the past 2 years to develop a modified allocation system that aims to reduce wait-list mortality.
Gilead and GlobeImmune Will Collaborate on Hepatitis B Therapeutic Vaccine
- Details
- Category: HBV Treatment
- Published on Friday, 28 October 2011 00:00
- Written by Gilead & GlobeImmune
Gilead Sciences and GlobeImmune announced this week that they will collaborate on the development and commercialization of a hepatitis B virus (HBV) therapeutic vaccine using GlobeImmune's Tarmogen yeast vector technology. In contrast to widely used HBV preventive vaccines, therapeutic vaccines are designed to stimulate the body's immune response to the virus, and may be used in conjunction with oral antiviral drugs.
Hepatitis Delta Found in 15% of HIV/HBV Coinfected People, Increases Risk of Death
- Details
- Category: Hepatitis Delta (HDV)
- Published on Thursday, 01 September 2011 00:00
- Written by Liz Highleyman
Approximately 15% of people with HIV who test positive for hepatitis B surface antigen (HBsAg) also carry hepatitis delta virus (HDV), a defective virus that can only replicate in the presence of hepatitis B virus (HBV) but can lead to more severe liver damage, according to a recent European study.
More Articles...
- High HBV Viral Load Predicts Liver Fibrosis and Cancer
- Long-Term Efficacy of Entecavir for People with Hepatitis B
- Deferoxamine Shows Promise for Liver Cancer in People with Advanced Disease
- Early HBeAg Decrease Predicts Response to Entecavir (Baraclude) for Hepatitis B
- Interpreting Hepatitis B Tests
Web Design and Development by